688526 Stock Overview
Focuses on the research and development, production, sales, and animal epidemic prevention technical services of veterinary biological products in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
Wuhan Keqian Biology Co.,Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥14.47 |
| 52 Week High | CN¥20.61 |
| 52 Week Low | CN¥11.00 |
| Beta | 0.65 |
| 1 Month Change | 3.88% |
| 3 Month Change | 7.19% |
| 1 Year Change | -26.88% |
| 3 Year Change | -47.48% |
| 5 Year Change | n/a |
| Change since IPO | -54.18% |
Recent News & Updates
The Market Lifts Wuhan Keqian Biology Co.,Ltd (SHSE:688526) Shares 38% But It Can Do More
Oct 09
These 4 Measures Indicate That Wuhan Keqian BiologyLtd (SHSE:688526) Is Using Debt Reasonably Well
Sep 26Recent updates
The Market Lifts Wuhan Keqian Biology Co.,Ltd (SHSE:688526) Shares 38% But It Can Do More
Oct 09These 4 Measures Indicate That Wuhan Keqian BiologyLtd (SHSE:688526) Is Using Debt Reasonably Well
Sep 26Investors Continue Waiting On Sidelines For Wuhan Keqian Biology Co.,Ltd (SHSE:688526)
Aug 20We Think Wuhan Keqian BiologyLtd (SHSE:688526) Can Stay On Top Of Its Debt
Jun 26Wuhan Keqian Biology Co.,Ltd (SHSE:688526) Stock Rockets 25% But Many Are Still Ignoring The Company
Apr 08Analysts Are More Bearish On Wuhan Keqian Biology Co.,Ltd (SHSE:688526) Than They Used To Be
Apr 05Earnings Miss: Wuhan Keqian Biology Co.,Ltd Missed EPS By 25% And Analysts Are Revising Their Forecasts
Apr 03Wuhan Keqian BiologyLtd (SHSE:688526) Has A Rock Solid Balance Sheet
Mar 20Shareholder Returns
| 688526 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -1.0% | -1.7% | -1.0% |
| 1Y | -26.9% | -4.3% | 10.8% |
Return vs Industry: 688526 underperformed the CN Pharmaceuticals industry which returned -4.3% over the past year.
Return vs Market: 688526 underperformed the CN Market which returned 10.8% over the past year.
Price Volatility
| 688526 volatility | |
|---|---|
| 688526 Average Weekly Movement | 7.6% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 13.0% |
| 10% least volatile stocks in CN Market | 5.8% |
Stable Share Price: 688526 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688526's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 903 | Mulin Chen | www.kqbio.com |
Wuhan Keqian Biology Co.,Ltd focuses on the research and development, production, sales, and animal epidemic prevention technical services of veterinary biological products in China. The company offers vaccines for pigs, poultry, and pets, as well as diagnostic reagents. Wuhan Keqian Biology Co.,Ltd was founded in 2001 and is based in Wuhan, China.
Wuhan Keqian Biology Co.,Ltd Fundamentals Summary
| 688526 fundamental statistics | |
|---|---|
| Market cap | CN¥6.68b |
| Earnings (TTM) | CN¥299.11m |
| Revenue (TTM) | CN¥902.14m |
22.5x
P/E Ratio7.4x
P/S RatioIs 688526 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688526 income statement (TTM) | |
|---|---|
| Revenue | CN¥902.14m |
| Cost of Revenue | CN¥344.01m |
| Gross Profit | CN¥558.13m |
| Other Expenses | CN¥259.02m |
| Earnings | CN¥299.11m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.64 |
| Gross Margin | 61.87% |
| Net Profit Margin | 33.16% |
| Debt/Equity Ratio | 1.5% |
How did 688526 perform over the long term?
See historical performance and comparisonDividends
3.0%
Current Dividend Yield67%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 09:27 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Wuhan Keqian Biology Co.,Ltd is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Xie Zhiyou | China Galaxy Securities Co., Ltd. |
| Junhao Fan | China International Capital Corporation Limited |
| Siyang Wang | China International Capital Corporation Limited |